SCM
CABA icon

Stonepine Capital Management’s Cabaletta Bio CABA Stock Holding History

Stonepine Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
917,100
+867,100
+1,734% +$2.85M 1.61% 23
2026
Q1 		$135K Sell
50,000
-121,100
-71% -$336K 0.05% 77
2025
Q4 		$375K Buy
+171,100
New +$424K 0.27% 53

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Stonepine Capital Management's CABA Position: Q2 2026 in Review

Stonepine Capital Management increased its Cabaletta Bio (CABA) stake by 1,734% in Q2 2026, buying an estimated $2.85M and bringing the position to 917,100 shares worth $2.85M. The position accounts for 1.61% of the portfolio, ranked #23.

Stonepine Capital Management first reported a position in CABA in Q4 2025 and has held it in 3 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Stonepine Capital Management held 917,100 shares of Cabaletta Bio worth $2.85M as of Q2 2026.
  • Stonepine Capital Management bought 867,100 Cabaletta Bio shares in Q2 2026, an estimated $2.85M.
  • Cabaletta Bio made up 1.61% of Stonepine Capital Management's portfolio in Q2 2026, its #23 holding.
  • Stonepine Capital Management first reported a position in Cabaletta Bio in Q4 2025 and has held it in 3 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.